Patents by Inventor Harold A. Heitzmann

Harold A. Heitzmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250107928
    Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
    Type: Application
    Filed: December 13, 2024
    Publication date: April 3, 2025
    Inventors: David S. Haffner, Kenneth M. Curry, Harold A. Heitzmann, David Applegate
  • Publication number: 20250107929
    Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
    Type: Application
    Filed: December 13, 2024
    Publication date: April 3, 2025
    Inventors: David S. Haffner, Kenneth M. Curry, Harold A. Heitzmann, David Applegate
  • Patent number: 12208034
    Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: January 28, 2025
    Assignee: Dose Medical Corporation
    Inventors: David S. Haffner, Thomas W. Burns, Harold A. Heitzmann, Kenneth M. Curry
  • Patent number: 12201557
    Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
    Type: Grant
    Filed: November 30, 2022
    Date of Patent: January 21, 2025
    Assignee: Dose Medical Corporation
    Inventors: David S. Haffner, Kenneth M. Curry, Harold A. Heitzmann, David Applegate
  • Patent number: 12201555
    Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: January 21, 2025
    Assignee: Dose Medical Corporation
    Inventors: David S. Haffner, Kenneth M. Curry, Harold A. Heitzmann, David Applegate
  • Patent number: 12186237
    Abstract: Devices and methods for treating intraocular pressure are disclosed. The devices include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The shunts are preferably implanted by ab interno procedures.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: January 7, 2025
    Assignee: Glaukos Corporation
    Inventors: Thomas W. Burns, David Steven Haffner, Harold A. Heitzmann, Todd N. Fjield, Richard A. Hill
  • Publication number: 20240207091
    Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. In several embodiments, the devices are capable of controlled release of two or more drugs, the release of each drug into a different ocular space (e.g., an ocular compartment versus an ocular fluid outflow pathway).
    Type: Application
    Filed: January 9, 2024
    Publication date: June 27, 2024
    Inventors: Harold A. Heitzmann, Thomas W. Burns, David S. Haffner
  • Patent number: 11925578
    Abstract: Certain aspects relate to drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye. In several embodiments, the devices are capable of controlled release of two or more drugs, the release of each drug into a different ocular space (e.g., an ocular compartment versus an ocular fluid outflow pathway).
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: March 12, 2024
    Assignee: Glaukos Corporation
    Inventors: Harold A. Heitzmann, Thomas W. Burns, David S. Haffner
  • Publication number: 20240065887
    Abstract: Disclosed herein are drug delivery implants configured to be implanted into the eye of a subject and serve as intraocular drug depots. The implants reside in an intraocular target site until activation, at which time the implants release the drug (or drugs) housed within the implant in a controlled release fashion.
    Type: Application
    Filed: August 18, 2023
    Publication date: February 29, 2024
    Inventors: Harold A. Heitzmann, Thomas W. Burns, David S. Haffner
  • Publication number: 20230301830
    Abstract: Disclosed herein are drug delivery ocular implants comprising an elongate outer shell having a proximal end, and distal end and being shaped to define an interior lumen, at least one therepautic agent positioned within the lumen, wherein the outer shell has at least a first thickness, the outer shell comprises one or more regions of drug release, and the implant is dimensioned for implantation within the anterior chamber of the eye.
    Type: Application
    Filed: May 1, 2023
    Publication date: September 28, 2023
    Inventors: Harold Heitzmann, Vanessa Tasso
  • Publication number: 20230157868
    Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
    Type: Application
    Filed: January 9, 2023
    Publication date: May 25, 2023
    Inventors: David S. Haffner, Thomas W. Burns, Harold A. Heitzmann, Kenneth M. Curry
  • Publication number: 20230090539
    Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
    Type: Application
    Filed: November 30, 2022
    Publication date: March 23, 2023
    Inventors: David S. Haffner, Kenneth M. Curry, Harold A. Heitzmann, David Applegate
  • Publication number: 20230053931
    Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
    Type: Application
    Filed: August 26, 2022
    Publication date: February 23, 2023
    Inventors: David S. Haffner, Thomas W. Burns, Harold A. Heitzmann, Kenneth M. Curry
  • Patent number: 11564569
    Abstract: An implantable intraocular physiological sensor for measuring intraocular pressure, glucose concentration in the aqueous humor, and other physiological characteristics. The implantable intraocular physiological sensor may be at least partially powered by a fuel cell, such as an electrochemical glucose fuel cell. The implantable intraocular physiological sensor may wirelessly transmit measurements to an external device. In addition, the implantable intraocular physiological sensor may incorporate aqueous drainage and/or drug delivery features.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: January 31, 2023
    Assignee: GLAUKOS CORPORATION
    Inventors: Thomas W. Burns, Harold A. Heitzmann, Kenneth Martin Curry, David S. Haffner, David Applegate, Bruce Nogales
  • Publication number: 20220330819
    Abstract: An implantable intraocular physiological sensor for measuring intraocular pressure, glucose concentration in the aqueous humor, and other physiological characteristics. The implantable intraocular physiological sensor may be at least partially powered by a fuel cell, such as an electrochemical glucose fuel cell. The implantable intraocular physiological sensor may wirelessly transmit measurements to an external device. In addition, the implantable intraocular physiological sensor may incorporate aqueous drainage and/or drug delivery features.
    Type: Application
    Filed: June 20, 2022
    Publication date: October 20, 2022
    Inventors: Thomas W. Burns, Harold A. Heitzmann, Kenneth Martin Curry, David S. Haffner, David Applegate, Bruce Nogales
  • Patent number: 11426306
    Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: August 30, 2022
    Assignee: DOSE MEDICAL CORPORATION
    Inventors: David S. Haffner, Thomas W. Burns, Harold A. Heitzmann, Kenneth M. Curry
  • Publication number: 20220233349
    Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
    Type: Application
    Filed: February 18, 2022
    Publication date: July 28, 2022
    Inventors: David S. Haffner, Thomas W. Burns, Harold A. Heitzmann, Kenneth M. Curry
  • Patent number: 11363951
    Abstract: An implantable intraocular physiological sensor for measuring intraocular pressure, glucose concentration in the aqueous humor, and other physiological characteristics. The implantable intraocular physiological sensor may be at least partially powered by a fuel cell, such as an electrochemical glucose fuel cell. The implantable intraocular physiological sensor may wirelessly transmit measurements to an external device. In addition, the implantable intraocular physiological sensor may incorporate aqueous drainage and/or drug delivery features.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: June 21, 2022
    Assignee: GLAUKOS CORPORATION
    Inventors: Thomas W. Burns, Harold A. Heitzmann, Kenneth Martin Curry, David S. Haffner, David Applegate, Bruce Nogales
  • Patent number: 11253394
    Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: February 22, 2022
    Assignee: Dose Medical Corporation
    Inventors: David S. Haffner, Thomas W. Burns, Harold A. Heitzmann, Kenneth M. Curry
  • Publication number: 20220000663
    Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
    Type: Application
    Filed: June 9, 2021
    Publication date: January 6, 2022
    Inventors: David S. Haffner, Thomas W. Burns, Harold A. Heitzmann, Kenneth M. Curry